Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 23:39:10 - browse：9359

A heart monitoring watch, referred as Project Zero 2.0 is displayed in the Omron Healthcare booth during a press event – health tech coverage from STAT — Digital tools to better track blood pressure over time and encourage adherence to treatment plans are increasingly commonplace. David Becker/Getty Images

If you have high blood pressure, it’s increasingly likely that your doctor or your insurer will offer you a blood pressure cuff or an educational app to help you get it under control. While potentially impactful, these tools may not be reaching marginalized people who don’t regularly have access to good health care — and who may benefit the most from the tools.

A new analysis suggests that there ought to be more investment in novel hypertension programs for people experiencing health disparities.The meta-review of 28 studies of digital health interventions for people of color and low-income patients found that as a whole participants saw a statistically significant and clinically meaningful reduction in average systolic blood pressure compared to control groups. In total, the analysis included more than 8,000 participants; most of the studies followed participants for six or 12 months. The results, published Wednesday in JAMA Network Open, are consistent with studies of digital tools in the general population.

Joseph Ebinger, of the Smidt Heart Institute at Cedars-Sinai in Los Angeles, who was not involved in the study, said it provides needed evidence that “there are tools that exist to be able to help meet individuals where they are in the world, and they should be utilized more heavily.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Why getting cancer drugs just got harder for rural patients

WSS

House looks to weaken Medicare negotiation

Overprescribed: High cost isn't America's only drug problem

Clinical trials giant ICON acquires HumanFirst

Overprescribed: High cost isn't America's only drug problem

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Medicare Advantage 2025 payments will dip, Biden administration says

focus

Wikipedia

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Bird flu reported in person exposed to presumably infected cattle

Virginia high school admissions case could be legal follow

Hundreds died while taking an arthritis drug, but nobody alerted patients

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Duchenne breakthrough therapy leaves behind pioneering families

AstraZeneca loses challenge to Medicare drug price negotiation

Apple is now the first public company to be valued at $3 trillion

Insurer loopholes limit power of law against surprise medical bills

knowledge

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Clinical trials giant ICON acquires HumanFirst

Obesity now affects over 1 billion people worldwide, study finds

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

International team creates first chimeric human

Clinical trials giant ICON acquires HumanFirst

focus

explore

focus

hotspot